NeuroBo Pharmaceuticals, Inc. - Common Stock (NRBO)
2.3600
0.00 (0.00%)
Neurobo Pharmaceuticals is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases and other severe conditions
Through its cutting-edge research and development efforts, the company aims to create transformative treatments that address significant unmet medical needs in areas such as cognition, memory, and overall brain health. By harnessing advanced technology and scientific insights, Neurobo strives to improve patient outcomes and enhance the quality of life for individuals affected by debilitating neurological disorders.
NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit Virtual Conference presentations are now available for on-demand viewing.
CAMBRIDGE, MA / ACCESSWIRE / November 11, 2024 / NeuroBo Pharmaceuticals, Inc. (NASDAQNRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview at the Q4 Investor Summit. The company will be available for 1-on-1 meetings throughout the day in addition to its presentation.
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 250 points on Thursday. The Dow traded up 0.66% to 38,403.91 while the NASDAQ rose 1.01% to 15,316.80. The S&P 500 also rose, gaining, 0.87% to 4,887.70.
Shares of C.H. Robinson Worldwide, Inc. (NASDAQCHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results.
U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 0.5% on Thursday. The Dow traded up 0.23% to 38,238.99 while the NASDAQ rose 0.54% to 15,245.46. The S&P 500 also rose, gaining, 0.48% to 4,868.71.
NeuroBo announced that the FDA has cleared its IND application for DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR). The company plans to initiate a Phase 1 clinical trial, for the treatment of obesity, in the first half of 2024.
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Thursday. Following the market opening Thursday, the Dow traded up 0.14% to 38,204.88 while the NASDAQ rose 0.77% to 15,281.03. The S&P 500 also rose, gaining, 0.49% to 4,869.54.
NeuroBo Pharmaceuticals, Inc. (NASDAQNRBO) is one today’s most active stocks by volume. So far today, approximately 36,413 shares of NeuroBo Pharmaceuticals, Inc. have been exchanged, as compared to an average 30-day volume of 47,156 shares.
NeuroBo Pharmaceuticals, Inc. (NASDAQNRBO) shares are trading lower in Friday's premarket session after ending Thursday's session with a whopping 21.2% gain.
NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held December 14th. This event is sponsored by Zacks Small-Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend.
